List of Soolantra drug patents
Soolantra is owned by Galderma Labs Lp.
Soolantra contains Ivermectin.
Soolantra has a total of 12 drug patents out of which 0 drug patents have expired.
Soolantra was authorised for market use on 19 December, 2014.
Soolantra is available in cream;topical dosage forms.
Soolantra can be used as treatment of inflammatory lesions of rosacea..
The generics of Soolantra are possible to be released after 13 March, 2034.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11033565 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(1 year, 2 months from now) | |
| US8470788 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(1 year, 2 months from now) | |
| US7550440 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(1 year, 2 months from now) | |
| US8815816 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(1 year, 2 months from now) | |
| US8093219 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(1 year, 2 months from now) | |
| US8080530 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(1 year, 2 months from now) | |
| US8415311 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(1 year, 2 months from now) | |
| US9089587 | GALDERMA LABS LP | Treatment of papulopustular rosacea with ivermectin |
Mar, 2034
(11 years from now) | |
| US9233117 | GALDERMA LABS LP | Treatment of inflammatory lesions of rosacea with ivermectin |
Mar, 2034
(11 years from now) | |
| US9782425 | GALDERMA LABS LP | Treatment of papulopustular rosacea with ivermectin |
Mar, 2034
(11 years from now) | |
| US10206939 | GALDERMA LABS LP | Treatment of papulopustular rosacea with ivermectin |
Mar, 2034
(11 years from now) | |
| US9233118 | GALDERMA LABS LP | Treatment of papulopustular rosacea with ivermectin |
Mar, 2034
(11 years from now) | |
Drugs and Companies using IVERMECTIN ingredient
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of inflammatory lesions of rosacea.
Dosage: CREAM;TOPICAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic